Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases

(2019) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management

(2019) Marlies Wijsenbeek et al.   CURRENT MEDICAL RESEARCH AND OPINION

The therapy of idiopathic pulmonary fibrosis: what is next?

(2019) Vivien Somogyi et al.   European Respiratory Review

Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease

(2018) Elizabeth F. Redente et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

What's in a name? That which we call IPF, by any other name would act the same

(2018) Athol U. Wells et al.   EUROPEAN RESPIRATORY JOURNAL

Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model

(2018) Wan Qin et al.   RADIATION RESEARCH

Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model

(2018) Jingwen Guo et al.   TOXICOLOGY LETTERS

Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis

(2017) Rokhsana Rasooli et al.   INFLAMMATION

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases

(2017) Frank Hilberg et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

(2017) Jürgen Behr et al.   BMC Pulmonary Medicine

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

(2016) D. Khanna et al.   JOURNAL OF RHEUMATOLOGY

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

(2016) Steven D Nathan et al.   THORAX

Fibrosis — A Common Pathway to Organ Injury and Failure

(2015) Don C. Rockey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

(2014) Wim A Wuyts et al.   Lancet Respiratory Medicine

An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

(2013) William D. Travis et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function

(2013) Shelley L. Schmidt et al.   CHEST

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis

(2011) J. L. Hook et al.   EUROPEAN RESPIRATORY JOURNAL

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Interstitial lung disease guideline

(2008) A U Wells et al.   THORAX